In September, Pfizer through its corporate venturing unit invested $5m in TetraLogic.
TetraLogic Pharmaceuticals, a US-based developer of anti-cancer drugs backed by pharmaceutical company Pfizer, has raised $6m in its extended series C round from venture capital firm Nextech Invest.
In September, Pfizer through its corporate venturing unit invested $5m in TetraLogic.
Pfizer Ventures’ investment extended TetraLogic’s series C round, which originally closed in August at $32m.
Amgen Ventures, the $100m corporate venturing division of biotech company Amgen, and venture capital firms Clarus Ventures, which led the C round,…
